Market Place
Sourcing Support
FDA Grants Fast Track Designation to LB-P8 for Treatment of PSC
01 Apr 2024 //
CONTRACT PHARMA
LISCure receives U.S. FDA Fast Track designation for LB-P8 for the PSC
29 Mar 2024 //
PR NEWSWIRE
LISCure Announces FDA Clearance of IND Application to Initiate Phase 2 of LB-P8
29 Feb 2024 //
PR NEWSWIRE
Celltrion & LISCure announce collaboration for Parkinson`s disease
20 Feb 2023 //
PR NEWSWIRE
LISCure`s Phase 2 Drug Candidate Granted ODD from US FDA
08 Dec 2022 //
PRNEWSWIRE
LISCure Biosciences Announces Oral Presentation of New Drug Candidate for NASH
28 Oct 2022 //
PRNEWSWIRE
Abbott and LISC Team Up to Address Diversity and Equity Gaps in Supply Chain
30 Mar 2022 //
PRNEWSWIRE
LISCure Biosciences announces research collaboration with Mayo Clinic
06 Jan 2022 //
PRNEWSWIRE
LISCure Biosciences received clinical approval for two microbiome programs
30 Sep 2021 //
PRNEWSWIRE
LISCure inks know-how license pact and stock purchase agreement with Mayo Clinic
02 Aug 2021 //
PHARMABIZ
LISCure Biosciences How License Agreement ,Stock Purchase Agreement Mayo Clinic
26 Jul 2021 //
PRNEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.